MAGEA3 and non-small cell lung carcinoma: A recently concluded phase III clinical trial utilized MAGEA3 as an adjuvant immunotherapeutic agent for NSCLC patients, but the disease-free survival rate did not improve (Vansteenkiste et al., 2016).